Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
filibuvir + peginterferon alfa-2a + ribavirin
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral (filibuvir, Ribavirin), Subcutaneous (peginterferon Alfa-2a)
01
Overview
Filibuvir + peginterferon alfa-2a + ribavirin is an experimental triple combination regimen for the treatment of chronic hepatitis C virus (HCV) infection. Filibuvir is a non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, developed to block viral replication. Peginterferon alfa-2a is a pegylated form of interferon alfa—an immunomodulatory cytokine—that exerts antiviral effects by inducing an antiviral state within host cells and modulating the immune response. Ribavirin is a nucleoside analog antiviral, acting as a mutagen and immunomodulator, that has been widely used in combination with interferon-based regimens to enhance antiviral efficacy. While peginterferon alfa-2a plus ribavirin is a well-established dual regimen for HCV, the addition of filibuvir as a specifically targeted antiviral (a direct-acting antiviral) was studied to improve virologic response, particularly in difficult-to-treat HCV genotypes.Filibuvir development was discontinued and this triple combination has not been approved for use.
- Other names
- filibuvir + peginterferon alfa-2a + ribavirin
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)vRNA (Coronavirus viral RNA)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on filibuvir + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on filibuvir + peginterferon alfa-2a + ribavirin.